Puma Biotechnology Inc (PBYI): Price and Financial Metrics
PBYI Price/Volume Stats
| Current price | $4.98 | 52-week high | $7.73 |
| Prev. close | $5.13 | 52-week low | $2.13 |
| Day low | $4.97 | Volume | 36,069 |
| Day high | $5.14 | Avg. volume | 555,147 |
| 50-day MA | $5.62 | Dividend yield | N/A |
| 200-day MA | $4.16 | Market Cap | 240.07M |
PBYI Stock Price Chart Interactive Chart >
Puma Biotechnology Inc (PBYI) Company Bio
Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.
Latest PBYI News From Around the Web
Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
PBYI Price Returns
| 1-mo | -10.91% |
| 3-mo | 0.61% |
| 6-mo | 107.50% |
| 1-year | 83.09% |
| 3-year | -51.03% |
| 5-year | -85.09% |
| YTD | 15.01% |
| 2023 | 2.36% |
| 2022 | 39.14% |
| 2021 | -70.37% |
| 2020 | 17.26% |
| 2019 | -57.00% |
Continue Researching PBYI
Want to do more research on Puma Biotechnology Inc's stock and its price? Try the links below:Puma Biotechnology Inc (PBYI) Stock Price | Nasdaq
Puma Biotechnology Inc (PBYI) Stock Quote, History and News - Yahoo Finance
Puma Biotechnology Inc (PBYI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...